SABS — SAB Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $258.40m
- $158.97m
SAB Biotherapeutics slumps as NIH halts trial of COVID drug candidate
Brief: Sab Biotherapeutics Reports NIH Is Discontinuing Phase 3 Activ-2 Trial Assessing Sab-185
Brief: Sab Biotherapeutics Announces Update To The Phase 3 Nih Activ-2 Trial Design Evaluating Sab-185 For Treatment Of Covid-19
Brief: Sab Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating Sab-185 Met Criteria For Advancement To Phase 3 In Nih Activ-2 Trial For Treatment Of Covid-19
U.S. STOCKS ON THE MOVE-Tesla, Delta Air Lines, Accenture, Calliditas Therapeutics
U.S. STOCKS ON THE MOVE-Accenture, Lennar, Novavax, Calliditas Therapeutics
Brief: SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
SAB Biotherapeutics up after treatment shows promise against Omicron in lab test
U.S. RESEARCH ROUNDUP-Beyondspring, Okta, Vocera Communications
U.S. STOCKS ON THE MOVE-Ambarella, BeyondSpring, OceanPal, Allbirds
U.S. STOCKS ON THE MOVE-Box, BeyondSpring, Build-A-Bear Workshop, OceanPal
U.S. STOCKS ON THE MOVE-CTI BioPharma, Aditxt, OceanPal, Ardelyx
SAB Biotherapeutics surges after flu treatment meets study goal
Brief: Sab Biotherapeutics Announces Sab-176 Met Its Primary Endpoint In Phase 2A Challenge Study In Adults Infected With Influenza Virus
NASDAQ RESUMED AT 07:30 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Sab Biotherapeutics Reports Q3 Financial Results
U.S. STOCKS ON THE MOVE-Ralph Lauren, Dell, Avis Budget, DuPont